DE60030429D1 - Neuronale, die exozytose hemmende peptide und diese enthaltende kosmetische und pharmazeutische zusammensetzungen - Google Patents

Neuronale, die exozytose hemmende peptide und diese enthaltende kosmetische und pharmazeutische zusammensetzungen

Info

Publication number
DE60030429D1
DE60030429D1 DE60030429T DE60030429T DE60030429D1 DE 60030429 D1 DE60030429 D1 DE 60030429D1 DE 60030429 T DE60030429 T DE 60030429T DE 60030429 T DE60030429 T DE 60030429T DE 60030429 D1 DE60030429 D1 DE 60030429D1
Authority
DE
Germany
Prior art keywords
cosmetic
pharmaceutical compositions
exocytosis
neuronals
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60030429T
Other languages
English (en)
Other versions
DE60030429T2 (de
DE60030429T3 (de
Inventor
Mira M Clara Blanes
Hernandez M Mercedes Llobregat
Tebar Ana Isabel Gil
Ballester Gregorio J Fernandez
Cases Rosa M Planell
Montiel Antonio Vicente Ferrer
Bover Salvador Viniegra
Perez Luis Miguel Gutierrez
Castell Teresa Carbonell
Paya Enrique Perez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipotec SA
Original Assignee
Lipotec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8308129&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60030429(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipotec SA filed Critical Lipotec SA
Application granted granted Critical
Publication of DE60030429D1 publication Critical patent/DE60030429D1/de
Publication of DE60030429T2 publication Critical patent/DE60030429T2/de
Publication of DE60030429T3 publication Critical patent/DE60030429T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
DE60030429T 1999-04-23 2000-02-18 Neuronale, die exozytose hemmende peptide und diese enthaltende kosmetische und pharmazeutische zusammensetzungen Expired - Lifetime DE60030429T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES009900844A ES2160485B1 (es) 1999-04-23 1999-04-23 Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
ES9900844 1999-04-23
PCT/ES2000/000058 WO2000064932A1 (es) 1999-04-23 2000-02-18 Peptitos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen
EP00905076A EP1180524B2 (de) 1999-04-23 2000-02-18 Neuronale, die exozytose hemmende peptide und diese enthaltende kosmetische und pharmazeutische zusammensetzungen

Publications (3)

Publication Number Publication Date
DE60030429D1 true DE60030429D1 (de) 2006-10-12
DE60030429T2 DE60030429T2 (de) 2007-10-31
DE60030429T3 DE60030429T3 (de) 2012-01-12

Family

ID=8308129

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60030429T Expired - Lifetime DE60030429T3 (de) 1999-04-23 2000-02-18 Neuronale, die exozytose hemmende peptide und diese enthaltende kosmetische und pharmazeutische zusammensetzungen

Country Status (12)

Country Link
US (2) US7015192B1 (de)
EP (1) EP1180524B2 (de)
JP (2) JP4363556B2 (de)
AT (1) ATE338062T1 (de)
AU (1) AU2672900A (de)
BR (2) BRPI0011152B8 (de)
CA (1) CA2370289C (de)
DE (1) DE60030429T3 (de)
DK (1) DK1180524T4 (de)
ES (1) ES2160485B1 (de)
PT (1) PT1180524E (de)
WO (1) WO2000064932A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
US7807780B2 (en) 2000-07-21 2010-10-05 Revance Therapeutics, Inc. Multi-component biological transport systems
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
FR2846885B1 (fr) * 2002-11-13 2004-12-24 Oreal Utilisation d'une association de composants a effet synergique inhibiteur de canaux calciques pour prevenir ou traiter les ridules
US7071167B2 (en) 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
JP2004323400A (ja) * 2003-04-23 2004-11-18 Mikimoto Pharmaceut Co Ltd 皮膚外用剤
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
AU2005251676B2 (en) 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
SG10201803560WA (en) 2004-03-03 2018-06-28 Revance Therapeutics Inc Compositions And Methods For Topical Application And Transdermal Delivery Of Botulinum Toxins
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
BRPI0517917B1 (pt) * 2004-11-02 2020-11-10 Dsm Ip Assets B.V. compostos, sais de adição de ácido, método para preparar os compostos, uso de compostos, composição topicamente aplicável, e, método para o tratamento de rugas de expressão e/ou relacionadas com a idade em pele humana
AU2006218431B2 (en) 2005-03-03 2012-12-06 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1856139B1 (de) * 2005-03-03 2011-04-27 Revance Therapeutics, Inc. Zusammensetzungen und methoden zur topischen anwendung und zur transdermalen verabreichung eines oligopeptids
ES2259928B1 (es) * 2005-04-08 2007-11-01 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica que comprende peptidos derivados de encefalinas para reducir y/o eliminar arrugas faciales.
BRPI0618753A2 (pt) 2005-11-17 2011-09-13 Revance Therapeutics Inc composição para liberação transdérmica de toxina botulìnica e método de administração
EP1976869A2 (de) * 2005-12-23 2008-10-08 Partnership&Corp. Technology Transfer Synthetische peptide zur verwendung als inhibitoren der neurotransmittersekretion und als induktoren der muskelrelaxation
ES2322882B1 (es) * 2006-10-25 2010-04-22 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal.
EP1992332A1 (de) * 2007-05-08 2008-11-19 Tupperware Products S.A. Kosmetische Anti-Aging-Hautpflegezusammensetzungen
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
ES2527022T3 (es) 2009-07-24 2015-01-19 Lipotec, S.A. Compuestos inhibidores de la contracción muscular
US20130078295A1 (en) * 2010-06-09 2013-03-28 Lipotec S.A. Skin antiaging treatment
US20110305735A1 (en) * 2010-06-09 2011-12-15 Lipotec, S.A. Skin antiaging treatment
ES2385683B1 (es) * 2010-10-18 2013-10-07 Bcn Peptides, S.A. Composiciones para el tratamiento del dolor y/o la inflamación.
EP2802337B2 (de) * 2011-11-07 2021-01-20 Feng Tian Peptidverbindungen als hemmer einer neurotransmittersekretion
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
US10149812B2 (en) 2012-04-13 2018-12-11 Activen Cosmetic composition comprising a muconopeptide
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
KR102113994B1 (ko) 2012-04-13 2020-05-25 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 신경세포 세포외배출(ii)을 억제하는 화합물
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
CN104334155B (zh) 2012-04-13 2017-06-16 艾克迪文 包含μ芋螺肽的化妆品组合物
JP2016535770A (ja) 2013-11-01 2016-11-17 スフェリウム バイオメッド エス．エル． 治療用及び美容用物質を経皮送達するための封入体
TWI728957B (zh) 2014-10-31 2021-06-01 美商盧伯利索先進材料有限公司 用於傳送活性劑至皮膚表面的熱塑性聚胺基甲酸酯膜及其用途和形成方法
CN104478991B (zh) * 2014-12-10 2018-06-19 深圳市维琪医药研发有限公司 一种新型多肽化合物及其制备方法和其医药应用
CN104829691B (zh) * 2015-05-19 2018-11-02 山西锦波生物医药股份有限公司 除皱短肽及其制备方法
CN108473652A (zh) 2015-11-05 2018-08-31 路博润先进材料公司 可热成型的双网络水凝胶组合物
JP7296642B2 (ja) 2018-02-27 2023-06-23 リポトゥルー，エセ．エレ． 化粧料および医薬に使用するためのペプチドおよび組成物
EP3807293A1 (de) 2018-06-13 2021-04-21 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Peptide mit hemmender wirkung auf neuronale exozytose
US20230190616A1 (en) 2018-08-10 2023-06-22 Lubrizol Advanced Materials, Inc. Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes
MA53932A (fr) 2018-10-16 2021-08-25 Glo Pharma Inc Compositions de conotoxine servant d'antagonistes peptidiques des récepteurs nicotiniques de l'acétylcholine et méthodes associées
MX2020014330A (es) 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
EP4144337A1 (de) 2021-09-02 2023-03-08 Guangzhou Jiyan Cosmetics Technology Co. Ltd. Kosmetische zusammensetzung aus vitis vinifera
EP4230638A1 (de) 2022-02-16 2023-08-23 Lipotrue, S.L. Peptide und zusammensetzungen zur verwendung in kosmetika
WO2023161264A1 (en) 2022-02-23 2023-08-31 Prospera Biotech, S.L. Compositions for treating hyperhidrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034620A1 (en) * 1996-03-18 1997-09-25 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.

Also Published As

Publication number Publication date
US20060276392A1 (en) 2006-12-07
ES2160485B1 (es) 2002-05-16
CA2370289A1 (en) 2000-11-02
DK1180524T3 (da) 2006-12-11
JP2009221223A (ja) 2009-10-01
CA2370289C (en) 2011-04-19
WO2000064932A1 (es) 2000-11-02
PT1180524E (pt) 2007-01-31
JP2002542777A (ja) 2002-12-17
DK1180524T4 (da) 2010-10-25
EP1180524B2 (de) 2010-07-07
US7473679B2 (en) 2009-01-06
ATE338062T1 (de) 2006-09-15
BRPI0011152B8 (pt) 2022-05-10
BR0011152A (pt) 2002-02-19
JP4892037B2 (ja) 2012-03-07
JP4363556B2 (ja) 2009-11-11
ES2160485A1 (es) 2001-11-01
DE60030429T2 (de) 2007-10-31
EP1180524B1 (de) 2006-08-30
DE60030429T3 (de) 2012-01-12
AU2672900A (en) 2000-11-10
EP1180524A1 (de) 2002-02-20
BRPI0011152B1 (pt) 2018-03-13
US7015192B1 (en) 2006-03-21

Similar Documents

Publication Publication Date Title
DE60030429D1 (de) Neuronale, die exozytose hemmende peptide und diese enthaltende kosmetische und pharmazeutische zusammensetzungen
ES2176285T3 (es) Amidas y esteres de peptidos inhibidoras del cancer de seres humanos.
ATE338771T1 (de) Antagonisten des intestinotrophen glp-2 peptides
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
CY1106898T1 (el) Χρηση d-σερινης ή d-αλανινης για την αντιμετωπιση της σχιζοφρενειας
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
LV10720A (lv) Peptidi un farmaceitiska kompozicija uz to bazes
CY1109981T1 (el) Αναλογα του gaba για την προληψη και αγωγη γαστρεντερικης βλαβης
DK0794961T3 (da) LHRH-antagonistpeptider
FI962557A (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
TR200103469T2 (tr) Amiloidojenik hastalığının önlenmesi ve tedavisi
DE69532996D1 (de) Peptidanaloge des menschlichen basischen myelinproteins
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
NO20001869L (no) FremgangsmÕte for behandling av Alzheimers sykdom
DK2380583T3 (da) Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
WO2002074956A3 (en) Dopaminergic neuronal survival-promoting factors and uses thereof
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
DE69503724D1 (de) L-Carnitin-Salz, dieses enthaltende kosmetische und pharmazeutische Zusammensetzungen zur Behandlung von Dermatosen
ATE233812T1 (de) Peptide mit pronociceptiveigenschaften
ATE345809T1 (de) Arzneimittelzusammensetzung enthaltend tcf-ii
PT655244E (pt) Composicao a base de acidos aminados para o tratamento de infeccoes
TR199501328A2 (tr) Alzheimer peptidi.
ATE31418T1 (de) Arzneimittel, welche tripeptide enthalten.
DE59108261D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: LIPOTEC, S.A., GAVA, BARCELONA, ES

8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8332 No legal effect for de
R074 Re-establishment allowed

Ref document number: 1180524

Country of ref document: EP

R074 Re-establishment allowed

Ref document number: 1180524

Country of ref document: EP